Clinical Catch-Up: December 21-25 | BioSpace
The Pharma Data
DECEMBER 27, 2020
Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study of monoclonal antibody VIR-7831 for hospitalized adults with COVID-19. The drug is a humanized IgG4 monoclonal antibody that blocks CCR5 and is being developed for COVID-19, HIV and metastatic triple-negative breast cancer.
52 
Let's personalize your content